ライフサイエンスコーパス: insurer

1 t survives to care for helpless young ("life insurers").

2 diagnosis and had Medicare as their primary insurer.

3 e manufacturer to the distributor and to the insurer.

4 Setting: Claims from a large national health insurer.

5 that were submitted to a large, national US insurer.

6 th for the laboratory and for the patient or insurer.

7 rom a large, national US managed care health insurer.

8 64 years enrolled in a large national health insurer.

9 ht thing" may not be covered by the payer or insurer.

10 Claims from a large national health insurer.

11 applied for insurance, 60% were rejected by insurers.

12 gical malpractice claims from four liability insurers.

13 has been adopted for use by many commercial insurers.

14 ison groups of enrollees covered by the same insurers.

15 edures covered by Medicare and other private insurers.

16 corporate hospital chains and large private insurers.

17 guideline recommended and widely covered by insurers.

18 e extent of genetic discrimination by health insurers.

19 d for treatment, 28% were denied coverage by insurers.

20 , state governments, and private health care insurers.

21 d concurrent ACO contracting with commercial insurers.

22 supported by public healthcare or by private insurers.

23 he accuracy of network directories posted by insurers.

24 ter hospital pricing leverage against health insurers.

25 lenges to patients, families, providers, and insurers.

26 alth care expenditures borne by patients and insurers.

27 administrative data of a U.S. private health insurer (2000-2007 claims) to identify depression diagno

28 administrative data of a U.S. private health insurer (2000-2007 claims) to identify postdonation canc

29 007) to billing claims from a private health insurer (2000-2007 claims) to identify renal condition d

30 o administrative data of a US private health insurer (2000-2007 claims), we examined associations of

31 inked to billing records of a private health insurer (2003-2006 claims).

32 In 2009, the VA billed private insurers $52.3 million to reimburse care provided to MA

33 $36.4 billion; Medicaid, $3.3 billion; other insurers, $9.6 billion; patients, $48.6 billion; and inc

34 testing if employers (93/117; 79.5%), health insurers (90/117; 76.9%), or life insurers (92/117; 78.6

35 %), health insurers (90/117; 76.9%), or life insurers (92/117; 78.6%) could access results.

36 ecords, changes in reporting requirements of insurers, advocacy on the part of patients, and incorpor

37 ved from the largest German statutory health insurer, Allgemeine Ortskrankenkassen (AOK).

38 patient payment, as that cost is set by the insurer and may depend on rebates from the manufacturer

39 administrative data of a private U.S. health insurer and performed a retrospective study of 4650 pers

40 By using both in-person interviews with insurers and a direct market test, we found that a perso

41 Although insurers and agents are only vaguely aware of these laws

42 inatory use of genetic information by health insurers and employers.

43 The new law requires that insurers and health plans provide coverage for individua

44 The increasing involvement of insurers and hospitals in monitoring patient care is enc

45 From the perspective of the insurers and patients, between 2009 and 2012, hospital-o

46 Ophthalmologists should work with insurers and pharmacists to prevent such discontinuation

47 rom failure to articulate to the public (and insurers and policymakers) what value it, and it alone,

48 In this market-driven system, insurers and providers compete not so much by increasing

49 and sharing of health care information among insurers and providers have been pursued.

50 ned detailed summaries of the cases from the insurers and reviewed the litigation files if the outcom

51 The results should be of great interest to insurers and the research community as they consider per

52 Cancer advocates, insurers, and government agencies also have important ro

53 at it would be most meaningful to hospitals, insurers, and government agencies responsible for health

54 orldwide attention from professional groups, insurers, and governments.

55 of strategies affecting potential enrollees, insurers, and healthcare providers are offered.

56 Policymakers, insurers, and institutional review boards all have a rol

57 mptomatic genetic test results to employers, insurers, and others.

58 ers (general dental practitioners, patients, insurers, and policy makers) from the Netherlands, Germa

59 It is important that patients, physicians, insurers, and policymakers understand the relationship b

60 e improvements in coding, reimbursement from insurers, and research funding, and widespread education

61 ancial value to patients, public and private insurers, and society.

62 y of the insurance plans, risk adjustment of insurers, and solidarity.

63 Patients, hospitals, insurers, and the public rely on competent physicians.

64 ne public payer); free choice of provider or insurer; and expansion of services to poor people and th

65 mmunicate with risk managers, attorneys, and insurers; and finally, so that we can better understand

66 ancer clinical trials, although many private insurers are concerned about the expense of this effort.

67 Certain Florida-based insurers are denying patients access to bariatric surger

68 Many private insurers are following Medicare's lead.

69 Insurers are increasingly deploying "narrow networks" wi

70 Insurers are well positioned to participate in public-pr

71 post-donation nephrectomy benefits with this insurer at some point from 2000 through 2007.

72 Although insurers bear the brunt of treatment costs for OA, the O

73 ng strategies that involve financial risk to insurers can reduce budgeted health expenditures.

74 Malpractice insurers can use this information to guide malpractice r

75 , 2004 to December 31, 2010 using commercial insurer claims data.

76 Data were abstracted from a commercial insurer claims database in 12 states and analyzed from J

77 episodes), and hospital expenditures paid by insurers (commercial or governmental) during the 180-day

78 A malpractice insurer convened a collaborative with 4 Harvard-affiliat

79 The third-party insurer cost perspective average cost-utility ratio was

80 spective is more likely than the third-party insurer cost perspective to demonstrate a greater financ

81 ective, which is the same as the third-party insurer cost perspective, includes the costs an insurer

82 was performed using societal and third-party insurer cost perspectives.

83 analysis using the societal and third-party insurer cost perspectives.

84 Insurer coverage decisions for GH in specific case scena

85 NCCN) Compendium recommendations, a basis of insurer coverage policies.

86 For this hospital system in which private insurers covered 40% of patients (13,544), Medicare cove

87 The third-party insurer CUR for bilateral ranibizumab therapy was $4587/

88 bursement of transplantation costs abroad by insurers; (d) ambivalence of the victim status of the se

89 Limited private insurer data also were obtained.

90 ween 2006 and 2009 linked to provincial drug insurer data on all drugs dispensed from community-based

91 on making and the interplay of physician and insurer decisions in determining access to care.

92 s can save over 35% from a public healthcare insurer drug formulary while maintaining or improving pa

93 re almost no well-documented cases of health insurers either asking for or using presymptomatic genet

94 alculated the administrative costs of health insurers, employers' health benefit programs, hospitals,

95 n and restricts access to medical records by insurers, employers, and clinical researchers.

96 into our everyday lives, even to inform how insurers evaluate our health.

97 eased OOP expenditures by $694 per annum and insurer expenditures by $4,036.

98 tures by $1,379 per annum (2007 dollars) and insurer expenditures by $4,833.

99 Of that amount, insurer expenditures were $149.4 billion and OOP expendi

100 m, new payment incentives implemented by one insurer for an accountable care organization (ACO) may a

101 ueried the claims database of a large health insurer for patients hospitalized for MI or with ATH.

102 ers of those surveyed reported pressure from insurers for early discharge; nearly two-thirds said hos

103 cated by government agencies and third-party insurers for the care of these individuals.

104 target indoor environmental exposures, most insurers generally have not covered the outreach, educat

105 period to determine whether the malpractice insurer had closed the case.

106 ere questioned about whether the hospital or insurers had pressured them to change their inpatient pr

107 Insurers have a vested interest because individually und

108 Insurers have expressed concerns that these mandates wil

109 however, is rationing these drugs, and other insurers have restricted coverage due to their exorbitan

110 Private insurers have similar provisions for children and adults

111 providers, patient advocates, agencies, and insurers have the responsibility and opportunity to prov

112 cancer community from physicians, patients, insurers, hospitals, and industry.

113 ors analyzed claims data from a large health insurer in New England.

114 years or younger covered by 3 of the largest insurers in the United States-United HealthCare, Aetna,

115 Calendar year 2002 claims data from 2 large insurers in Washington state were analyzed for provider

116 direct reimbursement, part of a strategy by insurers, including Medicare and private insurance compa

117 ity measures at the clinician, hospital, and insurer level has created challenges and logistical prob

118 Evidence suggests insurers limit access to trials because of cost concerns

119 Among insurers, Medicaid stood out as a low and slow payer, bu

120 nment agencies, hospital and health systems, insurers, medical societies, health care quality consort

121 urer cost perspective, includes the costs an insurer might be expected to pay, including those for ph

122 medical claims data from a large national US insurer (N = 4,387,651).

123 Medicare, 14 states, and several private insurers now cover the costs of patient care in "qualify

124 Purpose Health insurers offer plans covering a narrow subset of provide

125 Under reference pricing, the insurer or employer establishes a maximum contribution i

126 e received requests from patients to deceive insurers (OR, 2.44; 95% CI, 1.72-3.45); (3) feel pressed

127 patient annually, measured in terms of what insurers paid to the physician organizations for profess

128 Many insurers participating in the new insurance exchanges ar

129 It is hoped that this overview will assist insurers/payors in reimbursing transplant centers for so

130 minimizing costs because a third party (the insurer) pays the bill.

131 g financial concentration in health systems, insurers, pharmacies, and benefit managers; (2) informat

132 Most insurers, physicians, hospital administrators, legislato

133 Insurers, physicians, hospitals, and other providers fac

134 H therapy for children with Turner syndrome, insurer policies covered GH therapy for only 52% of thes

135 en used to justify traditionally restrictive insurer policies regarding clinical trials.

136 effectiveness to guide clinical practice and insurer policies.

137 r clinical trials is often not reimbursed by insurers, primarily because of concern that medical care

138 tional representative surveys were mailed to insurers (private, Blue Cross/Blue Shield, health mainte

139 Private insurers ranked last (0.04% of revenue) and health syste

140 rivacy must be protected; public and private insurers rarely pay for electronic communication with pa

141 data indicated considerable variation among insurers regarding coverage policies for GH (P<.01).

142 Additionally, fear of insurer reimbursement denial can be a significant barrie

143 Yet, the financial costs to patients and insurers remain poorly understood.

144 were covered by Medicaid or other nonprivate insurers remained relatively steady throughout the study

145 tween 1985 and 2001 with a large malpractice insurer representing one third of the physicians in Mass

146 ect spending and quality of care for another insurer's enrollees served by the ACO.

147 are becoming available as public and private insurers shift reimbursement to reward better health out

148 tian, and other health professionals; health insurers should make these resources available to genera

149 urce utilization, major coronary events, and insurer spending.

150 Health insurers, state regulators, and federal lawmakers should

151 izes primary care physicians; and 4) private insurers tend to pay for procedures, but not for office

152 Insurers that provide these plans can exit Medicaid prog

153 It is incumbent on insurers, their regulators, and the policy community to

154 th insurance claims records of a New England insurer to assess the relation between salmeterol and se

155 pport and participation of other health care insurers to adequately fund GME.

156 power increases because it is difficult for insurers to bargain successfully with one of only a few

157 losed malpractice claims from five liability insurers to determine whether a medical injury had occur

158 es are being used by an increasing number of insurers to ensure that medical care is provided by high

159 hat affect it is necessary for providers and insurers to optimize health outcomes for patients and sh

160 when the Affordable Care Act (ACA) required insurers to permit children to remain on parental polici

161 d programs have increasingly contracted with insurers to provide medical care services for enrollees

162 the financial risk of health care costs from insurers to providers, as has been done with the Medicar

163 CER is to empower the government and private insurers to reduce health care costs by restricting acce

164 h has prompted efforts by public and private insurers to steer patients toward the lower-priced optio

165 Because insurers use performance and quality metrics to inform r

166 1, 28 states have enacted laws that prohibit insurers' use of genetic information in pricing, issuing

167 and differential payment rates by commercial insurers vs Medicare.

168 percent; the overhead among Canada's private insurers was higher than that in the United States (13.2

169 Using data from malpractice insurers, we analyzed the claims experience of chiroprac

170 Insurers were asked coverage decisions for GH therapy.

171 n was defined by the standard method used by insurers, which is a hospital stay that exceeds the Diag

172 In addition, government-based and private insurers will be expecting documentation of the paramete

173 grams being introduced by Medicare and other insurers will link provider revenues to quality indicato

174 ss, these laws have made it less likely that insurers will use genetic information in the future.

175 re covered by a large professional liability insurer with a nationwide client base (40,916 physicians

176 work created by having to deal with multiple insurers with different rules, often designed to avoid p

177 Insurers would also tailor benefit packages and develop

178 children with idiopathic short stature, but insurers would not cover GH for the vast majority of the

179 Health insurers would respond to the demands of individual cons